Andrew Berens
Stock Analyst at Leerink Partners
(1.23)
# 3,569
Out of 4,944 analysts
94
Total ratings
45.24%
Success rate
-11.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $52.32 | +14.68% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $12.21 | +47.42% | 5 | Jul 7, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.06 | +27.48% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $3.27 | +83.77% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $36.45 | +53.64% | 11 | Sep 27, 2024 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $77.62 | +1.78% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.61 | +228.73% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $7.17 | +457.88% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $2.32 | +2,787.93% | 1 | Oct 14, 2021 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $78.70 | +77.89% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.30 | +1,334.78% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $13.56 | +84.37% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $119.67 | -19.78% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $84.62 | -7.82% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $66.22 | -27.51% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $10.86 | +157.83% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.51 | +1,688.08% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.54 | +340.53% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.03 | +255.62% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $12.74 | -37.21% | 7 | Jul 14, 2017 |
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $52.32
Upside: +14.68%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $12.21
Upside: +47.42%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.06
Upside: +27.48%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $3.27
Upside: +83.77%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $36.45
Upside: +53.64%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $77.62
Upside: +1.78%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.61
Upside: +228.73%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $7.17
Upside: +457.88%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.32
Upside: +2,787.93%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $78.70
Upside: +77.89%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.30
Upside: +1,334.78%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $13.56
Upside: +84.37%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $119.67
Upside: -19.78%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $84.62
Upside: -7.82%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $66.22
Upside: -27.51%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $10.86
Upside: +157.83%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.51
Upside: +1,688.08%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.54
Upside: +340.53%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $7.03
Upside: +255.62%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $12.74
Upside: -37.21%